(Press-News.org) (WASHINGTON, March 10, 2014) – A pill that suppresses a key regulator of cancer growth may provide hope to relapsed leukemia and lymphoma patients running out of treatment options for their aggressive, treatment-resistant disease, according to three reports* published online today in Blood, the journal of the American Society of Hematology.
Patients with blood cancer are typically administered a combination of chemotherapy and immunotherapy, the latter using the body's own immune system to help fight disease, as a first line of treatment. While chemotherapy has traditionally been successful in destroying cancer cells, it is accompanied by many harmful side effects and patients typically develop resistance, prompting researchers to investigate new targeted therapies that may be able to block the production of cancer cells while leaving normal cells unharmed.
One such targeted therapy, called idelalisib, is a highly selective compound that, unlike chemotherapy, can target a specific mechanism that fuels cancer growth. Taken as a pill, idelalisib first targets and then blocks the expression of the delta isoform of the PI3 kinase enzyme, which is critical for the activation and survival of cancerous B cells. Idelalisib's narrow targeting of the PI3 kinase delta make it an attractive potential therapy for patients with cancers that form in the B-cell pathway such as chronic lymphocytic leukemia (CLL), indolent non-Hodgkin lymphoma (iNHL), and mantle cell lymphoma (MCL). While idelalisib is currently under review by the U.S. Food and Drug Administration (FDA) for the treatment of treatment-resistant iNHL, another drug in its class called ibrutinib, which specifically targets a different cell regulator, has been approved as a second-line therapy for CLL and MCL.
"Idelalisib is a part of a revolutionary new class of treatments that can hone in on a specific target without causing the wide range of side effects seen with chemotherapy," said study author Jennifer R. Brown, MD, PhD, Director of the Chronic Lymphocytic Leukemia Center at Dana-Farber Cancer Institute in Boston.
In three manuscripts published today in Blood, investigators present data from a large Phase I study evaluating the safety and efficacy of idelalisib in more than 150 patients with CLL, iNHL, and MCL. Before joining the trial, patients had received several previous treatments – some as many as 14 – that either failed to destroy the disease or provided only a temporary reprieve. After an initial study involving all trial participants, patients were separated into CLL, iNHL, and MCL disease cohorts and received varied doses of idelalisib. The therapy appeared to be effective, as patients suffered few side effects and demonstrated promising response rates, with 72 percent of CLL patients, 47 percent of iNHL patients, and 40 percent of MCL patients achieving either a complete or partial response.
"Considering the high number of previous therapies that these patients had received, higher than we sometimes see in comparable studies, the efficacy of idelalisib that we observed was remarkable," said study author Ian Flinn, MD, PhD, Director of the Hematologic Malignancies Research Program at Sarah Cannon Research Institute in Nashville and a widely recognized expert in lymphoma. "It was this initial excitement that has inspired further studies of this therapy in patients with treatment-resistant blood cancers."
While patients in the CLL and iNHL cohorts experienced significant and prolonged reduction of disease activity, patients with MCL, a more aggressive and treatment-resistant type of lymphoma, experienced less favorable responses. Despite MCL patients' high overall response rate of 40 percent to idelalisib, the duration of their response to the drug was not as impressive; only a small fraction (22%) enjoyed prolonged benefits. Despite the modest duration of survival facilitated by idelalisib in the MCL group, the strong response rate suggests that investigators have identified a key regulator of cancer growth; however, more research is needed to further understand the potential of this therapy in MCL patients.
"While idelalisib is unlikely to receive designation as a single-agent therapy in mantle cell lymphoma due to the short duration of response, the path forward will likely include administering it in combination with other agents or developing second-generation PI3 kinase inhibitors," said study author Brad S. Kahl, MD, Director of the Lymphoma Service at the University of Wisconsin Carbone Cancer Center in Madison. "This study offers a strong foundation for future research on idelalisib in this disease."
INFORMATION:
*Studies referenced in this release include:
Idelalisib, an Inhibitor of Phosphatidylinositol 3-Kinase p110δ, for relapsed/refractory chronic lymphocytic leukemia, Brown et al.
Idelalisib, a selective inhibitor of phosphatidylinositol 3-kinase-δ, as therapy for previously treated indolent non-Hodgkin lymphoma, Flinn et al.
Results of a phase I study of idelalisib, a PI3Kδ inhibitor, in patients with relapsed or refractory mantle cell lymphoma (MCL), Kahl et al.
Blood, the most cited peer-reviewed publication in the field of hematology, is available weekly in print and online. Blood is the official journal of the American Society of Hematology (ASH), the world's largest professional society concerned with the causes and treatment of blood disorders.
ASH's mission is to further the understanding, diagnosis, treatment, and prevention of disorders affecting blood, bone marrow, and the immunologic, hemostatic, and vascular systems by promoting research, clinical care, education, training, and advocacy in hematology.
blood® is a registered trademark of the American Society of Hematology.
Study finds pill may represent promising treatment for stubborn blood cancers
2014-03-10
ELSE PRESS RELEASES FROM THIS DATE:
Moffitt Cancer Center pioneers worldwide standard in diagnosing melanoma
2014-03-10
Moffitt Cancer Center researchers have been instrumental in making significant improvements to the diagnostic procedure called sentinel node biopsy for melanoma patients and teaching this procedure to physicians from around the world.
Sentinel nodes are the first lymph nodes to which cancer cells from a primary tumor like melanoma will spread. In the sentinel node biopsy procedure, a radioactive tracer and a blue-colored dye are injected at or near the melanoma site on the skin and tracked to the first lymph node(s). These sentinel nodes are then surgically removed and ...
Genomic test to rule out obstructive CAD may reduce need for more invasive diagnostics
2014-03-10
New Rochelle, NY, March 10, 2014–Nearly $7 billion is spent each year in the U.S. on diagnostic testing of the estimated three million people with symptoms of obstructive coronary artery disease (CAD). A new blood test that detects specific genes activated in individuals with obstructive CAD could exclude the diagnosis without the need for imaging studies or more invasive tests, reducing health care costs, as described in an article in Population Health Management, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers. The article is available free on the Population ...
'Death stars' in Orion blast planets before they even form
2014-03-10
The Orion Nebula is home to hundreds of young stars and even younger protostars known as proplyds. Many of these nascent systems will go on to develop planets, while others will have their planet-forming dust and gas blasted away by the fierce ultraviolet radiation emitted by massive O-type stars that lurk nearby.
A team of astronomers from Canada and the United States has used the Atacama Large Millimeter/submillimeter Array (ALMA) to study the often deadly relationship between highly luminous O-type stars and nearby protostars in the Orion Nebula. Their data reveal ...
Gillian and Hadi spell double tropical trouble around Queensland
2014-03-10
On Friday, March 7 there were two tropical lows located east and west of Queensland, Australia. Those lows organized and intensified into Tropical Cyclone Gillian and Hadi and were caught together in one amazing image from NASA's Aqua satellite. While Gillian has already made one landfall and is expected to make another, Hadi is turning tail and running from the mainland.
NASA's Aqua satellite passed over Queensland on March 10 at 04:00 UTC and the Moderate Resolution Imaging Spectroradiometer instrument known as MODIS captured Tropical Cyclones Gillian in the Gulf of ...
Serpentine ecosystems shed light on the nature of plant adaptation and speciation
2014-03-10
Plants that live in unusual soils, such as those that are extremely low in essential nutrients, provide insight into the mechanisms of adaptation, natural selection, and endemism. A seminal paper by Arthur Kruckeberg from 1951 on serpentine plant endemism has served as a solid bedrock foundation for future research on the link between natural selection and speciation. A recent article in the American Journal of Botany focuses on how this paper has influenced subsequent research on local adaptation, evolutionary pathways, and the relationship between climate, soils, and ...
'Older people denied proper access to cancer care' according to Queen's study
2014-03-10
Older people globally are being denied proper access to cancer care, according to an editorial by Queen's University Belfast academic, Professor Mark Lawler of the Centre for Cancer Research and Cell Biology.
In an editorial in the BMJ (British Medical Journal) Professor Lawler said: "there is increasing evidence from around the world that elderly patients are being 'undertreated', leading to a 'survival gap' between older and younger patients.
"We need a fundamental change in cancer policy for the elderly patient. Our current practices are essentially ageist, as we ...
Diagnosing diseases with smartphones
2014-03-10
Smartphones are capable of giving us directions when we're lost, sending photos and videos to our friends in mere seconds, and even helping us find the best burger joint in a three-mile radius. But University of Houston researchers are using smartphones for another very important function: diagnosing diseases in real time.
The researchers are developing a disease diagnostic system that offers results that could be read using only a smartphone and a $20 lens attachment.
The system is the brainchild of Jiming Bao, assistant professor of electrical and computer engineering, ...
Loss of antioxidant protein Nrf2 represses regeneration of muscle lost to aging
2014-03-10
(SALT LAKE CITY)—Good news for lifelong exercisers: Along with its salutary effects on the heart, weight, and other facets of health, physical activity also helps to regenerate muscle mass, which tends to diminish as people age.
In a study published in the journal Free Radical Biology and Medicine, researchers from the University of Utah and other institutions found that aged mice lacking Nrf2 that underwent two weeks of endurance exercise stress on treadmills showed poor stem cell regeneration, which is likely to hinder the recovery of lost muscle mass. Nrf2 is protein ...
Scents and sustainability
2014-03-10
Fresh banana, a waft of flowers, blueberry: the scents in Shota Atsumi's laboratory in the UC Davis Department of Chemistry are a little sweeter than most. That's because Atsumi and his team are engineering bacteria to make esters -- molecules widely used as scents and flavorings, and also as basic feedstock for chemical processes from paints to fuels.
Their latest work is published March 9 in the journal Nature Chemical Biology.
Nearly all industrial chemicals, from artificial flavorings to paint, are derived from oil or gas, Atsumi said.
"Our motivation is to ...
Blind can 'hear' colors and shapes, show Hebrew U. researchers
2014-03-10
Jerusalem, March 9, 2014 -- What if you could "hear" colors? Or shapes? These features are normally perceived visually, but using sensory substitution devices (SSDs) they can now be conveyed to the brain noninvasively through other senses.
At the Center for Human Perception and Cognition, headed by Prof. Amir Amedi of the Edmond and Lily Safra Center for Brain Sciences and the Institute for Medical Research Israel-Canada at the Hebrew University of Jerusalem Faculty of Medicine, the blind and visually impaired are being offered tools, via training with SSDs, to receive ...